Author Archives: wesley

Policy Analysis and Guidance: Yunnan’s Routine Medical Consumables Delisting Notification

Yunnan Province’s Government Procurement and Tendering Center has issued a notification regarding the delisting of certain medical consumables under the routine listing work for batch 20250305. This move aims to optimize the market by removing products that no longer meet the listing criteria, ensuring quality and supply stability.

Key Policy Highlights

Delisting Criteria
- Basis: Products are delisted based on enterprise applications and supporting documentation.
- Purpose: To maintain high standards for medical consumables and ensure market efficiency.
Product Details
- Example: The notification includes products like the “一次性使用麻醉呼吸管路组件” (Disposable Anesthesia Breathing Circuit Component) manufactured by Henan Tuoren Medical Device Group Co., Ltd.
Contact Information
- Support: Enterprises can contact the medical device procurement department for further inquiries.

Policy Orientation and Industry Implications
The delisting initiative reflects Yunnan’s strategic focus on:

Market Optimization: Removing underperforming or non-compliant products to enhance overall market quality.
Quality Assurance: Ensuring that only products meeting stringent standards remain available.
Transparency: Providing clear communication channels for enterprises regarding listing and delisting processes.

Conclusion
Yunnan’s approach to delisting medical consumables underscores its commitment to maintaining a high-quality and efficient market. This policy supports the reliability of the medical consumables supply chain and ensures healthcare providers have access to essential, quality-assured products. Enterprises should stay informed of these updates to maintain compliance and market access.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25153&CatalogId=3

Policy Analysis and Guidance: Kunming’s Third Batch of Provincial Alliance Drug Volume-Linked Procurement

Kunming City has announced the results of its third batch of provincial alliance drug volume-linked procurement, with the selected drugs scheduled to be available for trading online starting April 1, 2025. This initiative aims to optimize drug procurement processes, reduce costs, and ensure the availability of quality medications through a volume-linked procurement mechanism.

Key Policy Highlights

Online Trading Catalog
- Details: The selected drugs for Kunming’s third batch of provincial alliance volume-linked procurement are detailed in Attachment 1.
- Discontinuation: Previously selected drugs from the same manufacturer and formulation, as well as some products from the first batch of Kunming’s volume-linked procurement, will be discontinued after the new selected drugs are listed.
Implementation Timeline
- Effective Date: Medical institutions and insured retail pharmacies can procure the selected drugs through Yunnan Province’s Medical Security Information Platform starting April 1, 2025.
Sample Registration
- Filing Requirements: Drugs marked as “Requires Filing” in Attachment 1 must complete the basic drug notification and promise filing process.
- Process: Relevant enterprises should complete filing with the Yunnan Provincial Drug Administration as per the displayed announcement and establish distribution relationships in the procurement system.
Procurement and Distribution
- Direct or Entrusted Delivery: Selected drugs can be delivered directly by the selected manufacturer or entrusted to a pharmaceutical distribution company.
- Contract Signing: Medical institutions, manufacturers, and distributors must sign procurement contracts electronically in the procurement system starting now.
System Access
- Account Registration: Relevant enterprises should register for the procurement subsystem as per the 2024 notification.

Policy Orientation and Industry Implications
The implementation of Kunming’s third batch of volume-linked procurement reflects the city’s strategic focus on:

Cost Efficiency: Reducing drug prices through centralized procurement while maintaining quality standards.
Supply Stability: Ensuring the availability of essential medications through a reliable procurement mechanism.
Transparency: Promoting clear contractual agreements and accountability mechanisms.

Conclusion
Kunming’s volume-linked procurement framework sets a benchmark for regional drug management, emphasizing efficiency, quality, and accessibility. Stakeholders, including manufacturers, distributors, and healthcare providers, should align their operations with these guidelines to optimize compliance and patient outcomes.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25178&CatalogId=3

Policy Analysis and Guidance: Yunnan Announces Second Supply Enterprises for National Drug Procurement

Yunnan Province’s Government Procurement and Tendering Center has issued an announcement regarding the declaration of second supply enterprises for the tenth batch of national centralized drug procurement. This initiative aims to ensure the stability of drug supply, address market gaps, and enhance the efficiency of the centralized procurement system.

Key Policy Highlights

Drug Scope and Qualification
- Drugs Included: The announcement covers 10 specific drug varieties, including esmolol injection, aminocaproic acid injection, and others.
- Eligibility: Enterprises that are not primary or first backup suppliers for these drugs in Yunnan can apply.
Price Declaration and Backup Enterprise Determination
- Price Limits: Enterprises must declare prices no higher than 1.5 times their winning price or the highest winning price for the same variety.
- Selection Criteria: The lowest bidder is selected as the backup enterprise; if prices are equal, enterprises producing their own raw materials have priority.
Submission and Bidding Details
- Submission Deadline: Materials must be submitted by 10:00 AM on April 2, 2025.
- Location: Kunming High-Tech Zone, Building 1, Transaction Building, No. 269 Kefa Road.
- Requirements: Materials must be sealed and accompanied by authorization documents.
Bidding and Opening Details
- Bidding Time: Same as submission deadline.
- Location: Same as submission location.

Policy Orientation and Industry Implications
The announcement reflects Yunnan’s strategic focus on:

Supply Chain Resilience: Ensuring continuous drug availability through diversified supply sources.
Market Adaptability: Adapting procurement strategies to meet evolving market conditions.
Transparency: Enhancing clarity and accessibility of procurement information for stakeholders.

Conclusion
Yunnan’s approach to determining second supply enterprises underscores its commitment to maintaining a stable and responsive pharmaceutical market. This policy supports the reliability of the centralized procurement system and ensures patient access to essential medications. Stakeholders should stay informed of these updates to maintain operational efficiency and compliance.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25181&CatalogId=3